User:MaryGaulke/sandbox/Terren Peizer mockup marked up

Terren Scott Peizer, is an investor , ; financier , ; and stock promoter founder, chairman and CEO of Ontrak. He is also chairman the founder of the Los Angeles-based investment company Acuitas Group Holdings, and is the CEO of Ontrak.

Peizer has held various senior executive positions within several technology and biotech companies. In the 1980s, and was employed by Goldman Sachs, First Boston and he was a bond trader at Drexel Burnham Lambert as a bond salesman.

Early life and education
Peizer was born in 1959, and raised in Beachwood, Ohio, a suburb of Cleveland. He graduated from the Wharton School of the University of Pennsylvania.

Early career and Drexel Burnham Lambert
In 1983, Peizer worked began his career at Goldman Sachs and First Boston, where he worked as a high yield bond salesman. After two years there he was interviewed by Michael Milken then hired Peizer as a bond salesman for a position at Drexel Burnham Lambert in 1985. Peizer received Even though Michael's brother Lowell disapproved of Peizer, he was hired nevertheless, and given a $3.5 million dollar salary, as well as and a $500,000 loan, so he could to invest in the partnership. Peizer worked directly under (and at the same desk as) Milken, whom he admired, sometimes pretending to be him on the phone, and calling him "Dad".

When investigations into Milken's illegal activities started, Peizer approached the investigators, and offered them agreed to provide material evidence, to prosecutors in exchange for immunity. Peizer later claimed he felt "compelled" to testify against Milken, although he (Peizer) was not specifically the subject of the investigation.

1989–2000
In 1989, after losing his job at Drexel Burnham Lambert (who were about to go bankrupt), Peizer moved back to his parents in Cleveland, and purchased a minor league basketball team, the Omaha Racers, which he sold again after about a year. . He sold his majority stake a year later.

Major deals and financial transactions
Following his departure from Drexel Burnham Lambert, Peizer took on leadership roles at a series of medical and technology companies and promoted their stocks. In Between 1991 and '95 Peizer was also he became Chairman & CEO of Urethane Technologies (then UTI Chemicals), which was producing produced bicycle tires. He exited the company in 1994; it The company had been making losses since its inception in 1985, and went bankrupt in 1997.

From 1993 to '95 he 1995, Peizer was the Chairman at of CMS Enhancements (a subsidiary of Ameriquest), which produced computer parts. From 1997 to '99 1999, Peizer he was president of Hollis-Eden, a pharmaceutical company that was developing a drug that would work against to treat HIV/AIDS , malaria, tuberculosis & biowarfare. In August 1999, Peizer raised money for became chairman of Tera Computer Company, a manufacturer of supercomputers , which allowed them to later buy out Cray Research. Peizer became chairman & director of Cray, until he stepped back one year later. At Tera, Peizer raised funding and led the acquisition of Cray from SGI in March 2000. The merged company took the name Cray, Inc. Peizer left the chairman role at Cray in December 2000 but stayed with the company as a director.

Financial vehicles
Over the years Peizer has used the following holding and investment companies to conduct business (listed roughly in chronological order):
 * Financial Group Holdings (California)
 * Beachwood Financial (California)
 * Wendover Financial (California)
 * Socius Capital Group (Delaware)
 * Socius CG II (Bermuda)
 * Crede Capital Group (Delaware)
 * Crede CG II (Bermuda)
 * Crede CG III (Bermuda)
 * Intellect Capital Group (Delaware)
 * Acuitas Group Holdings (California)
 * Acuitas Capital Group (California)
 * Acuitas Financial Group (California)
 * Optimus Capital Partners (Delaware)
 * Optimus CG II (Cayman Islands)
 * Optimus Life Sciences Capital Partners (Cayman Islands)

Prometa
Peizer founded Hythiam, an addiction treatment company, in 2004. According to Peizer, he became interested in addiction treatment because of his half-brother's struggles with addiction. In 2007, 60 Minutes and The Dallas Morning News have criticized Peizer for bypassing after Hythiam circumvented clinical studies and government approval when bringing his Prometa, a treatment program for methamphetamine addiction, to market.

In 2011, Hythiam changed its name to Catasys, retaining Peizer as chairman and CEO of the company.

2018–present
In 2018, Peizer became CEO and director of BioVie, a pharmaceutical company. In July 2020, Catasys, of which Peizer is chairman and CEO, changed its name to that of its Ontrak product.